MAXCYTE INC

MXCTNASDAQ

🏆 #4010 by market capEarnings Nov 16US Equity

$1.19▲ $0.03 (+2.15%)

Market closed · at close

🔔

Track MXCT

Get earnings, price moves & breaking news on Telegram

Track

24h▲ 2.1%

7d▼ 0.4%

14d▲ 0.4%

30d▼ 8.5%

ytd▼ 23.0%

1y▼ 25.2%

🏦Market Cap

$127M

Small Cap

📈Revenue Growth (YoY)

-13.2%

Declining

📊Gross Margin

79.2%

High

💵FCF Margin

—

⚖️P/S Ratio

3.8x

Fair

Otter Score

Fair

Trading Snapshot

Day Range: $1.18 – $1.20
52-Week Range: $0.64 – $1.87
Volume: $1.79B
Avg Volume: $1.83B
Shares Outstanding: 107.1M
Next Earnings: Nov 1, 2026

Fundamentals Snapshot

Annual Revenue: $33M
Last Q Revenue: $7M
P/E Ratio: —
P/S Ratio: 3.8x
EPS (TTM): $-0.33
Dividend Yield: —
Dilution (1yr): +1.5%

Why Investors Own MXCT

✓High-growth profile — revenue up +20.9% YoY with expanding US Equity exposure.
✓Healthy economics — 71% gross margin and 26% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

MAXCYTE INC

MXCT

Financial Trends

Revenue

$33M▼ −14.5% YoY

Gross Margin

81.2%▼ −0.6% YoY

Operating Income

−$45M▼ −11.5% YoY

Free Cash Flow

−$36M▲ +23.6% YoY

Shares Outstanding

106.4M▲ +1.5% YoY

Net Cash

$2M▼ −$8M YoY

StockOtter · stockotter.space

About MAXCYTE INC

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

🦦